Logo

ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

Share this

ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO Study for HIV-1 Infection

Shots:

  • The P-III TANGO study involves assessing of Tivicay (dolutegravir) + Epivir (lamivudine) vs tenofovir alafenamide fumarate (TAF) -containing regimen in patients with HIV-1 with maintained viral suppression for at least 6mos. on TAF containing regimen
  • The P-III TANGO study resulted in meeting its 1 EPs i.e- patients with plasma HIV-1 RNA ≥50 c/mL using the FDA snapshot algorithm @48wks.- no case of virologic withdrawal or resistance is observed
  • Tivicay (50mg) + Epivir (300mg) is a combination of INI and NRTI and has received approval in the US & EU for the treatment of HIV-1 infection with no ARV treatment history and no resistance to dolutegravir/lamivudine & INI class/lamivudine respectively

Click here to read full press release/ article | Ref: GSK | Image: Apex


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions